Hamad Medical Corporation in Doha, Qatar has announced the launch of two groundbreaking treatments for patients with treatment-resistant depression at its Mental Health Service at Mesaieed General Hospital. These treatments, Esketamine and Transcranial Magnetic Stimulation (TMS), offer new hope to individuals who have not responded to traditional antidepressants. Dr. Ovais Wadoo, a Senior Consultant at HMC, emphasizes the importance of these innovative options in providing patients with a new avenue for recovery.
Esketamine, an FDA-approved nasal spray, is administered in a clinical setting under the supervision of healthcare professionals. This treatment is particularly beneficial for individuals who have not found relief with other antidepressants. In addition to Esketamine, HMC will soon offer TMS therapy, which utilizes magnetic pulses to stimulate specific brain regions associated with mood regulation. Dr. Ovais explains that TMS is a non-invasive alternative for patients who cannot tolerate traditional medication side effects or have found them ineffective.
Global experts have recognized the significant efficacy of both Esketamine and TMS in alleviating symptoms of depression. Esketamine provides rapid relief for many patients who have not responded to other treatments, while TMS has been shown to produce lasting improvements in mood and functionality. These treatments offer new hope for those who have not had success with conventional therapies, enhancing their overall quality of life and functioning.
The launch of these advanced mental health treatments aligns with Qatar’s National Vision 2030 and the new National Health Strategy 2024 to 2030, which prioritize mental health as a critical component of overall well-being. By expanding access to innovative therapies, HMC is committed to fostering a healthier society and supporting the nation’s goal of enhancing the quality of healthcare services. These treatments represent a significant advancement in the field of mental health care in Qatar, providing new options for individuals struggling with treatment-resistant depression.
Overall, the introduction of Esketamine and TMS at HMC’s Mental Health Service represents a major step forward in the treatment of depression in Qatar. These innovative therapies offer new hope to patients who have not responded to traditional treatments, providing them with alternatives that can significantly improve their quality of life. By prioritizing mental health and expanding access to advanced treatments, HMC is playing a crucial role in fulfilling Qatar’s vision for a healthier society and enhanced healthcare services.
